Galera Therapeutics (GRTX) Competitors $0.03 +0.01 (+18.55%) As of 03:15 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock GRTX vs. CVM, CDIO, PMCB, TSBX, APLM, BTAI, MYNZ, GTBP, KTTA, and OMGAShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include CEL-SCI (CVM), Cardio Diagnostics (CDIO), PharmaCyte Biotech (PMCB), Turnstone Biologics (TSBX), Apollomics (APLM), BioXcel Therapeutics (BTAI), Mainz Biomed (MYNZ), GT Biopharma (GTBP), Pasithea Therapeutics (KTTA), and Omega Therapeutics (OMGA). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Its Competitors CEL-SCI Cardio Diagnostics PharmaCyte Biotech Turnstone Biologics Apollomics BioXcel Therapeutics Mainz Biomed GT Biopharma Pasithea Therapeutics Omega Therapeutics CEL-SCI (NYSE:CVM) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and valuation. Does the media favor CVM or GRTX? In the previous week, CEL-SCI's average media sentiment score of 0.00 equaled Galera Therapeutics'average media sentiment score. Company Overall Sentiment CEL-SCI Neutral Galera Therapeutics Neutral Which has more risk & volatility, CVM or GRTX? CEL-SCI has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Does the MarketBeat Community believe in CVM or GRTX? Galera Therapeutics received 50 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 54.35% of users gave Galera Therapeutics an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote. CompanyUnderperformOutperformCEL-SCIOutperform VotesNo VotesUnderperform Votes27100.00% Galera TherapeuticsOutperform Votes5054.35% Underperform Votes4245.65% Which has stronger earnings & valuation, CVM or GRTX? CEL-SCI is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$26.92M-$12.61-0.19Galera TherapeuticsN/AN/A-$59.08M-$0.35-0.09 Do insiders and institutionals hold more shares of CVM or GRTX? 12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 9.9% of CEL-SCI shares are owned by insiders. Comparatively, 12.9% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is CVM or GRTX more profitable? Galera Therapeutics' return on equity of 0.00% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -238.05% -104.65% Galera Therapeutics N/A N/A -99.34% SummaryGalera Therapeutics beats CEL-SCI on 9 of the 10 factors compared between the two stocks. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.08M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-0.098.6727.1419.96Price / SalesN/A262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book-0.016.597.064.69Net Income-$59.08M$143.75M$3.23B$248.14M7 Day PerformanceN/A3.72%2.67%2.39%1 Month PerformanceN/A11.01%8.82%6.05%1 Year PerformanceN/A3.87%31.44%13.60% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.03+18.5%N/A-72.4%$2.08MN/A-0.0930CVMCEL-SCI0.0716 of 5 stars$2.48+18.1%N/A-93.9%$7.52MN/A-5.1743High Trading VolumeCDIOCardio Diagnostics1.8087 of 5 stars$4.25+6.5%$60.00+1,311.8%-76.2%$7.39M$19.90K0.001Short Interest ↑PMCBPharmaCyte Biotech1.1177 of 5 stars$1.07+4.3%N/A-52.7%$7.34MN/A2.024Positive NewsShort Interest ↑TSBXTurnstone Biologics3.3047 of 5 stars$0.31-4.5%$0.45+43.9%-87.5%$7.24M$19.31M-0.1082Positive NewsShort Interest ↓Gap UpAPLMApollomics0.8633 of 5 stars$6.55+7.4%N/A-69.3%$7.23M$1.22M0.0045Gap UpBTAIBioXcel Therapeutics3.9021 of 5 stars$1.32+11.9%$42.60+3,127.3%-92.2%$7.15M$1.85M-0.0490Short Interest ↑MYNZMainz Biomed2.8339 of 5 stars$2.04+1.5%$14.00+586.3%-92.3%$7.02M$893.99K-0.0330Positive NewsGap DownGTBPGT Biopharma2.7087 of 5 stars$2.71+5.0%$11.00+305.9%+1.0%$7.01MN/A-0.488Positive NewsShort Interest ↑Gap UpKTTAPasithea Therapeutics1.6397 of 5 stars$0.93-4.1%N/A-84.8%$6.92MN/A-0.093News CoverageShort Interest ↓Gap DownOMGAOmega Therapeutics1.8134 of 5 stars$0.13-21.8%$9.20+7,260.0%-94.2%$6.92M$8.10M-0.09120Gap Up Related Companies and Tools Related Companies CVM Competitors CDIO Competitors PMCB Competitors TSBX Competitors APLM Competitors BTAI Competitors MYNZ Competitors GTBP Competitors KTTA Competitors OMGA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRTX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
